Small nuclear ribonucleoprotein polypeptide G (SNRPG)

Small nuclear ribonucleoprotein polypeptide G (SNRPG) is a core component of the major and minor spliceosomal small nuclear ribonucleoprotein complexes (U1, U2, U4, U5; and minor U12), playing a fundamental role in pre-mRNA splicing and associated RNA processing events[1][2][3]. SNRPG, an ~8.5 kDa Sm-class protein encoded by a gene on chromosome 2p13.3, participates in both the assembly and functional activity of the spliceosome by mediating complex protein-protein and protein-RNA interactions essential to the regulation of gene expression[1][2]. Dysregulation of SNRPG expression or function has been associated with various cancers and possibly with neurodegenerative diseases like spinal muscular atrophy[2]. In cancer, SNRPG overexpression correlates with disease progression and severity, and RNA interference experiments demonstrate that its suppression induces cell cycle arrest and enhances chemosensitivity, notably to temozolomide in glioblastoma models[1][3]. Due to its central role in cellular mRNA processing and its emerging links to cancer biology, SNRPG represents a potential molecular target for the development of novel anticancer therapeutics, particularly those designed to disrupt aberrant protein-protein interactions within the splicing machinery[1][3].

Other names

Smith protein GSmGSm-GSMGsnRNP-GPBSCGsmall nuclear ribonucleoprotein Gsm protein G

Modulation of RNA splicing machinery, influencing proliferation, cell cycle arrest, and apoptosis in cancer cells when targeted or silenced[1][3] Direct chemical interaction (hydrogen bonds, hydrophobic interactions) with temozolomide in molecular docking studies[3]